Related Experiment Video
Updated: Sep 13, 2025

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
Published on: October 4, 2019
Cassane diterpenoids with hepatic gluconeogenesis inhibitory activity from the seeds of Caesalpinia decapetala (Roth)
De-Sheng Wang1, Yu Shen2, Lin-Fen Ding3
1Key Laboratory of Ethnic Medicine Resource Chemistry, Ministry of Education, Yunnan Minzu University, Kunming, 650504, Yunnan, People's Republic of China; School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, 650500, People's Republic of China.
Abstract:
A chemical investigation of the seeds of Caesalpinia decapetala (Roth) Alston led to the isolation of fifteen cassane diterpenoids, including ten previously undescribed compounds (1-10) and five known analogues (11-15). The structures of 1-10 were determined using 1H, 13C, and 2D NMR, HRESIMS, and IR data. Their absolute configurations were confirmed by comparing experimental electronic circular dichroism data with calculated values, coupled with single-crystal X-ray diffraction analysis. Structurally, compounds 1 and 2 are rare cassane diterpenoids featuring a ketone carbonyl group at C-3. Excessive hepatic gluconeogenesis plays an important role in the occurrence and development of type 2 diabetes mellitus. In the present study, compounds 1, 3, 4, 6, 11, and 12 exhibited potent inhibitory effects on gluconeogenesis at a concentration of 20 μM in primary mouse hepatocytes, with inhibitory capacities of 68.2 ± 6.8 %, 78.4 ± 3.5 %, 53.8 ± 6.1 %, 94.8 ± 5.5 %, 85.1 ± 4.1 %, and 106.9 ± 2.9 %, respectively. Further studies indicated that these compounds inhibited gluconeogenesis in a dose-dependent manner across a concentration range from 1 to 50 μM. Notably, compounds 6 and 12 exhibited potent inhibitory effects on gluconeogenesis at a concentration of 2 μM, comparable to the effects of 500 μM metformin, suggesting their potential for ameliorating hyperglycemia.
More Related Videos
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Cell Specific Gene Expression
Oral Hypoglycemic Agents: Glinides
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

